Underrepresented Populations in Parkinson’s Genetics Research: Current Landscape and Future Directions
Output Details
Published January 31, 2022
- Review
Meet the Authors
-
Artur Francisco Shumacher-Schuh
External Collaborator
-
Andrei Bieger
External Collaborator
-
Olaitan Okunoye
External Collaborator
-
Kin Ying
External Collaborator
-
Shen-Yang Lim
External Collaborator
-
Soraya Bardien
External Collaborator
-
Azlina Ahman-Annuar
External Collaborator
-
Bruno Lopes Santos-Lobato
External Collaborator
-
Matheus Zschornack Strelow
External Collaborator
-
Mohamed Salama
External Collaborator
-
Shilpa C. Rao
External Collaborator
-
Yared Zenebe Zewde
External Collaborator
-
Saiesha Dindayal
External Collaborator
-
Jihan Azar
External Collaborator
-
Lingappa Kukkle Prashanth
External Collaborator
-
Roopa Rajan
External Collaborator
-
Alastair J Noyce
External Collaborator
-
Njideka Okubadejo
External Collaborator
-
Mie Rizig
External Collaborator
-
Suzanne Lesage
External Collaborator
-
Ignacia Fernandez Mata
External Collaborator
Related Research
Iron mishandling in the brain and periphery in Parkinson’s disease
The prodromal phase of Parkinson’s disease is complex. Gastrointestinal dysfunction and iron dysregulation may drive neurodegenerative risk. Identifying catalysts in the gut is crucial for developing disease-modifying therapies.
Adenosine in the brain: recent progress on detection, function and translation
Recent advancements have expanded our understanding of adenosine in the brain, revealing its role in regulating brain circuits for sleep, movement, cognition, and more.
Leucine Rich Repeat Kinase 2: Pathways to Parkinson’s Disease
Research on LRRK2 in Parkinson's disease has advanced, revealing how mutations activate the kinase, phosphorylate Rab proteins, disrupt cell functions like Hedgehog signaling, and contribute to the disease. LRRK2 inhibitors show promise for therapy.